睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07264816,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Toxicities from prior anti-tumor treatments have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;

    入选标准第 10 条

    Previously received HER2-targeted therapy or ADC drug treatment with camptothecin derivatives as toxins;

    排除标准第 3 条

  3. ECOG performance status score of 0 or 1;

    入选标准第 9 条

  4. Must have at least one measurable lesion meeting the RECIST v1.1 criteria;

    入选标准第 8 条

  5. Diagnosed with other primary malignancies within 5 years before the first dose;

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07264816,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily sign the informed consent form and comply with the protocol requirements;
  2. No gender restrictions;
  3. Age at the time of signing the informed consent form ≥18 years and ≤75 years;
  4. Expected survival time ≥3 months;
  5. Patients with locally advanced or metastatic non-squamous non-small cell lung cancer;
  6. Confirmed known HER2 overexpression;
  7. Agree to provide archived tumor tissue specimens from primary or metastatic lesions within the past 2 years;
  8. Must have at least one measurable lesion meeting the RECIST v1.1 criteria;
  9. ECOG performance status score of 0 or 1;
  10. Toxicities from prior anti-tumor treatments have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
  11. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  12. Organ function levels must meet the requirements;
  13. For premenopausal women with childbearing potential, a pregnancy test must be conducted within 7 days before starting treatment, serum pregnancy must be negative, and they must not be breastfeeding; all enrolled patients (regardless of gender) should take adequate and highly effective contraception throughout the treatment cycle and for 7 months after the end of treatment.

排除标准:Exclusion Criteria:

  1. Underwent surgical treatment, radical radiotherapy, immunotherapy, etc., within 4 weeks before the first dose or within 5 half-lives;
  2. Pathology indicates non-small cell carcinoma containing small cell carcinoma components and sarcomatoid carcinoma;
  3. Previously received HER2-targeted therapy or ADC drug treatment with camptothecin derivatives as toxins;
  4. History of severe cardiovascular or cerebrovascular diseases within the past 6 months before screening;
  5. Concurrent pulmonary disease leading to severe impairment of lung function;
  6. QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
  7. Diagnosed with other primary malignancies within 5 years before the first dose;
  8. Poorly controlled hypertension;
  9. History of non-infectious ILD requiring steroid treatment, or currently suffering from ILD/interstitial pneumonia, etc.;
  10. Patients with central nervous system metastases, carcinomatous meningitis, and/or spinal cord compression;
  11. Patients with a history of allergy to recombinant humanized antibodies or allergy to BL-M07D1, pembrolizumab, or any excipient components;
  12. Required systemic corticosteroid or immunosuppressive therapy within 2 weeks before the study administration;
  13. Patients with massive serous cavity effusion, symptomatic serous cavity effusion, or poorly controlled serous cavity effusion;
  14. New deep vein thrombosis within 14 days, excluding patients with venous filters implanted;
  15. Systemic severe infection within 4 weeks before screening;
  16. Active autoimmune diseases and inflammatory diseases;
  17. Human immunodeficiency virus antibody positivity, active hepatitis B virus infection, or hepatitis C virus infection;
  18. History of allogeneic stem cell, bone marrow, or organ transplantation;
  19. Presence of severe neurological or psychiatric disorders;
  20. Presence of other severe physical or laboratory abnormalities, poor compliance, etc., which may increase the risk of participation in the study, interfere with study results, or patients deemed unsuitable for participation in the study by the investigator.

引自 ClinicalTrials.gov, NCT07264816, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07264816,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07264816